Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891669 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01891669 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 26 participants.
The verdict
NCT01891669, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Interventions
- DRUG PF-06263507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-08-08 |
| Est. Completion | 2015-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01891669
The ClinicalTrials.gov registry entry for NCT01891669 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06263507 is the first listed.
NCT01891669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01891669 about?
NCT01891669 is a clinical study titled "A Study Of PF-06263507 In Patients With Advanced Solid Tumors". To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
What is the current status of trial NCT01891669?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-08-08. Estimated completion is 2015-06-29.
What interventions are being tested in trial NCT01891669?
The interventions under investigation include: PF-06263507 (DRUG).
Who is sponsoring clinical trial NCT01891669?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.